2-methyl-5-[2-(pyridin-3-yl)ethyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole | 1061352-64-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-methyl-5-[2-(pyridin-3-yl)ethyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole
• 英文别名: 2-Methyl-5-(2-(pyridin-3-yl)ethyl)-2,3,4,5-tetrahydro-1h-pyrido[4,3-b]indole；2-methyl-5-(2-pyridin-3-ylethyl)-3,4-dihydro-1H-pyrido[4,3-b]indole
• CAS: 1061352-64-4
• 化学式: C₁₉H₂₁N₃
• mdl: MFCD27214491
• 分子量: 291.396
• InChiKey: DICDOOGFHQRKKL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  21.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3-乙烯基吡啶 、 2-甲基-2,3,4,5-四氢-1H-吡啶并[4,3-b]吲哚 在 四正丁基硫酸铵 、 potassium hydroxide 作用下， 以 水 、 二甲基亚砜 为溶剂， 生成 2-methyl-5-[2-(pyridin-3-yl)ethyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole
  参考文献：
  名称：

  作为有效的5-HT 6受体拮抗剂的Dimebon新型γ-咔啉类似物的合成和生物学评估

  摘要：

  描述了一系列新的Dimebon ™ γ-咔啉类似物的合成，生物学评估和结构-活性关系。在研究的化合物中，已确定γ-咔啉3 {8}和3 { 14 }是组胺H 1（IC 50  = 0.1μM）和5-羟色胺5-HT 6（IC 50  = 0.37μM）受体的有效小分子拮抗剂。， 分别。

  DOI：

  10.1016/j.bmcl.2009.04.128

文献信息

• SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES, METHODS FOR USE THEREOF
  申请人：Ivachtchenko Alexandre Vasilievich

  公开号：US20190233409A1

  公开（公告）日：2019-08-01

  The present invention relates to compound of the formula 1.2, or a pharmaceutically acceptable salt, or hydrate thereof wherein R 1 is C 1 -C 5 alkyl; R 2 , is independently hydrogen, halogen, C 1 -C 3 alkyl, CF 3 , OCF 3 or OCH 3 ; i is 1, 2,3, or 4; Ar is unsubstituted phenyl or substituted phenyl substituted with halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, a substituted amino group or trifluoromethyl; or Ar is a substituted or unsubstituted 6-membered aromatic heterocycle one or, with two nitrogen atoms in the heterocycle; excluding the compounds of the formulas A1-A4 The invention relates to the novel chemical compounds, methods for their preparation and use as antagonists of 5-HT 6 receptors, simultaneously regulating homeostasis of calcium ions in cells. The invention relates to the novel annelated azaheterocycles—2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles, to methods for their preparation, to pharmaceutical compositions, including these compounds as active substances, and to methods of treatment and profylaxis of various diseases.

  本发明涉及公式1.2的化合物，或其药学上可接受的盐或水合物，其中R1为C1-C5烷基；R2独立地为氢、卤素、C1-C3烷基、CF3、OCF3或OCH3；i为1、2、3或4；Ar为未取代的苯基或取代的苯基，取代基为卤素、C1-C6烷基、C1-C6烷氧基、取代氨基或三氟甲基；或Ar为取代或未取代的6元芳杂环之一，其中异杂环中含有两个氮原子；但不包括A1-A4式的化合物。本发明涉及新的化学化合物、其制备方法以及作为5-HT6受体拮抗剂的用途，同时调节细胞内钙离子的稳态。本发明涉及新的螺合的氮杂环-2,3,4,5-四氢-1H-吡啶[4,3-b]吲哚化合物，以及其制备方法、包括这些化合物作为活性物质的制药组合物，以及各种疾病的治疗和预防方法。
• SUSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-B]INDOLES, METHODS FOR USE THEREOF
  申请人：Alla Chem, LLC

  公开号：US20130217703A1

  公开（公告）日：2013-08-22

  The present invention relates to a method of antagonizing a 5-HT 6 serotonin receptor and simultaneously regulating Ca +2 ion homeostasis in a cell, comprising administering to the cell a compound of formula 1, or a pharmaceutically acceptable salt thereof, wherein: R 1 is a C 1 -C 5 alkyl; R 2 i is independently hydrogen, halogen, a C 1 -C 3 alkyl, CF 3 , OCF 3 or OCH 3 ; i is 1, 2, 3 or 4; Ar is an unsubstituted phenyl or a substituted phenyl substituted with halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, substituted amino group or trifluoromethyl; or Ar is a substituted or unsubstituted 6-membered aromatic heterocycle with one or two nitrogen atoms in the heterocycle; and W is an ethylene group —CH 2 —CH 2 —, ethenyl group —CH═CH—, or ethynyl group —C≡C—. The invention also relates to new compounds selected from the group of compounds of the general formula 1, method for their preparation, pharmaceutical compositions and method for treating a cognitive disorder or neurodegenerative disease, or obesity in a subject in need thereof comprising administering an effective dose to the subject of a compound of formula 1 according to claim 1 , or a pharmaceutically acceptable salt thereof.

  本发明涉及一种拮抗5-HT6 5-羟色胺受体和同时调节细胞内Ca+2离子稳态的方法，包括向细胞中投与式1的化合物或其药学上可接受的盐，其中：R1是C1-C5烷基；R2独立地是氢、卤素、C1-C3烷基、CF3、OCF3或OCH3；i为1、2、3或4；Ar是未取代的苯基或取代的苯基，其被卤素、C1-C6烷基、C1-C6烷氧基、取代的氨基团或三氟甲基取代；或Ar是带有一个或两个氮原子的取代或未取代的6元芳香杂环；W是乙烯基—CH2—CH2—、乙烯基—CH═CH—或乙炔基—C≡C—。本发明还涉及从式1的化合物组中选择的新化合物、其制备方法、制备药物组合物的方法以及治疗认知障碍或神经退行性疾病或肥胖症的方法，包括向需要治疗的受体中投与式1的化合物或其药学上可接受的盐的有效剂量。
• Tetracyclic compounds
  申请人：HUNG David T.

  公开号：US20090239854A1

  公开（公告）日：2009-09-24

  This disclosure relates to new tetracyclic compounds that may be used to modulate a histamine receptor in an individual. The compounds in one embodiment are tetracyclic [4,3-b]indoles. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

  本公开涉及新的四环化合物，可用于调节个体中的组胺受体。在一种实施例中，该化合物为四环[4,3-b]吲哚。还提供了包含该化合物的药物组合物，以及使用该化合物进行各种治疗应用的方法，包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经元障碍。
• TETRACYCLIC COMPOUNDS
  申请人：MEDIVATION TECHNOLOGIES, INC.

  公开号：US20140194414A1

  公开（公告）日：2014-07-10

  This disclosure relates to new tetracyclic compounds that may be used to modulate a histamine receptor in an individual. The compounds in one embodiment are tetracyclic[4,3-b]indoles. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

  本文涉及新的四环化合物，可用于调节个体中的组胺受体。在其中一种实施方式中，这些化合物是四环[4,3-b]吲哚。还提供了包含这些化合物的制药组合物，以及使用这些化合物进行各种治疗应用的方法，包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经元障碍。
• LIGANDS OF ALPHA-ADRENOCEPTORS AND OF DOPAMINE, HISTAMINE, IMIDAZOLINE AND SEROTONIN RECEPTORS AND THE USE THEREOF
  申请人：Alla Chem, LLC.

  公开号：EP2236511A2

  公开（公告）日：2010-10-06

  The invention relates to novel ligands the broad spectrum of biological activity of which includes simultaneously α-adrenoceptors, dopamine receptors, histamine receptors, imidazoline receptors and serotonin receptors, among them serotonin 5-HT7 receptors, which are compounds of general formula 1 in the form of free bases, geometrical isomers, racemic mixtures or individual optical isomers, pharmaceutically acceptable salts and/or hydrates, wherein: R1 is a substituent of amino group, selected from hydrogen, optionally substituted C1-C4 alkyl, acyl, heterocyclyl, alkoxycarbonyl, substituted sulfonyl; R2 is a substituent of cyclic system, selected from hydrogen, halogen, optionally substituted C1-C4 alkyl, CF3, CN, alkoxy, alkoxycarbonyl, carboxyl, heterocyclyl or substituted sulfonyl; Ar is optionally substituted aryl not necessarily annalated with heterocyclyl, or optionally substituted aromatic heterocyclyl; W is optionally substituted (CH2)m group, optionally substituted CH=CH group, optionally substituted CH2-CH=CH group, C≡C group, SO2 group; n = 1, 2; m = 1, 2, 3; solid line accompanied by dotted line, i.e. (---) may represent single or double bond. The invention also relates to active ingredients, pharmaceutical compositions comprising the said ligands as active ingredients; to novel medicaments useful for treatment of diseases and conditions of central nervous system (CNS) of humans and warm-blooded animals.

  本发明涉及新型配体，其广泛的生物活性同时包括α-肾上腺素受体、多巴胺受体、组胺受体、咪唑啉受体和血清素受体，其中包括血清素5-HT7受体，这些配体是通式1化合物，其形式为游离碱、几何异构体、外消旋混合物或单个光学异构体、药学上可接受的盐和/或水合物、 其中R1 是氨基的取代基，选自氢、任选取代的 C1-C4 烷基、酰基、杂环基、烷氧羰基、取代的磺酰基； R2 是环状体系的取代基，选自氢、卤素、任选取代的 C1-C4 烷基、CF3、CN、烷氧基、烷氧羰基、羧基、杂环基或取代的磺酰基；Ar 是任选取代的芳基，不一定是环状杂环基，或任选取代的芳香族杂环基； W 是任选取代的 (CH2)m 基团、任选取代的 CH=CH 基团、任选取代的 CH2-CH=CH 基团、C≡C 基团、SO2 基团；n = 1、2；m = 1、2、3；实线伴有虚线，即.即（---）可代表单键或双键。 本发明还涉及活性成分、包含上述配体作为活性成分的药物组合物；涉及用于治疗人类和温血动物中枢神经系统（CNS）疾病和病症的新型药物。